Menu
← Oncology Approval Tracker
FDA DECISION ·
Trodelvy
sacituzumab govitecan-hziy · Gilead Sciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and at least two additional systemic regimens in the metastatic setting.
LAMPGEN ANALYSIS
Why it matters
The indication extended a TROP-2-directed antibody-drug conjugate to heavily pretreated HR-positive disease.
What research teams should watch
Verify receptor classification and count prior metastatic regimens before applying the label.
PRIMARY RECORDS